CNK-UT002

N/A

Report date: 2025/05/08 15:04:40

Base Information

Drug NameCNK-UT002
Drug Alias NameCNK-UT002CNKUT002
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunologic cytotoxicityNKG2D ligands modulatorsNatural cytotoxicity triggering receptor 2 Ligands modulators
TargetsNKG2D ligandsNatural cytotoxicity triggering receptor 2 Ligands
Therapy Area/IndicationsSolid tumoursLymphoma, T-CellLeukemia, T-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesST Phi Therapeutics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesST Phi Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLymphoma, T-CellLeukemia, T-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A